Kane Biotech Inc. (KNBIF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.46 Million CAD | -27.43% |
| 2022 | 4.77 Million CAD | -12.38% |
| 2021 | 5.45 Million CAD | 14.75% |
| 2020 | 4.75 Million CAD | 13.12% |
| 2019 | 4.2 Million CAD | 27.5% |
| 2018 | 3.29 Million CAD | -8.69% |
| 2017 | 3.6 Million CAD | 34.11% |
| 2016 | 2.69 Million CAD | 49.99% |
| 2015 | 1.79 Million CAD | 16.06% |
| 2014 | 1.54 Million CAD | -4.05% |
| 2013 | 1.61 Million CAD | 10.02% |
| 2012 | 1.46 Million CAD | 18.51% |
| 2011 | 1.23 Million CAD | 32.91% |
| 2010 | 929.4 Thousand CAD | 6.78% |
| 2009 | 870.35 Thousand CAD | -17.13% |
| 2008 | 1.05 Million CAD | -0.19% |
| 2007 | 1.05 Million CAD | 17.89% |
| 2006 | 892.58 Thousand CAD | -13.77% |
| 2005 | 1.03 Million CAD | 68.05% |
| 2004 | 615.97 Thousand CAD | 27.75% |
| 2003 | 482.18 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.21 Million CAD | 606.21% |
| 2024 Q2 | 1.46 Million CAD | 20.27% |
| 2023 FY | 3.69 Million CAD | -22.67% |
| 2023 Q3 | 1.51 Million CAD | 74.68% |
| 2023 Q1 | 1.36 Million CAD | 55.64% |
| 2023 Q2 | 866.22 Thousand CAD | -36.34% |
| 2023 Q4 | 172.29 Thousand CAD | -88.61% |
| 2022 Q2 | 1.36 Million CAD | -4.14% |
| 2022 Q4 | 874.29 Thousand CAD | -22.03% |
| 2022 FY | 4.77 Million CAD | -12.38% |
| 2022 Q1 | 1.42 Million CAD | -4.74% |
| 2022 Q3 | 1.12 Million CAD | -17.63% |
| 2021 Q2 | 1.09 Million CAD | -5.15% |
| 2021 Q1 | 1.14 Million CAD | -1.62% |
| 2021 FY | 5.45 Million CAD | 14.75% |
| 2021 Q3 | 1.72 Million CAD | 57.86% |
| 2021 Q4 | 1.49 Million CAD | -13.4% |
| 2020 Q2 | 711.44 Thousand CAD | -56.2% |
| 2020 Q1 | 1.62 Million CAD | 14.22% |
| 2020 Q4 | 1.16 Million CAD | -6.31% |
| 2020 FY | 4.75 Million CAD | 13.12% |
| 2020 Q3 | 1.24 Million CAD | 75.3% |
| 2019 Q2 | 1.03 Million CAD | 24.8% |
| 2019 Q4 | 1.42 Million CAD | 55.91% |
| 2019 FY | 4.2 Million CAD | 27.5% |
| 2019 Q3 | 912.05 Thousand CAD | -11.96% |
| 2019 Q1 | 830.12 Thousand CAD | 45.43% |
| 2018 Q4 | 570.81 Thousand CAD | -43.42% |
| 2018 Q2 | 771.71 Thousand CAD | -18.15% |
| 2018 FY | 3.29 Million CAD | -8.69% |
| 2018 Q3 | 1 Million CAD | 30.73% |
| 2018 Q1 | 942.89 Thousand CAD | 0.89% |
| 2017 Q4 | 934.56 Thousand CAD | 2.68% |
| 2017 Q3 | 910.16 Thousand CAD | 13.21% |
| 2017 Q2 | 803.98 Thousand CAD | -16.18% |
| 2017 FY | 3.6 Million CAD | 34.11% |
| 2017 Q1 | 959.13 Thousand CAD | 88.59% |
| 2016 Q4 | 508.57 Thousand CAD | -18.69% |
| 2016 Q1 | 617.12 Thousand CAD | 32.29% |
| 2016 FY | 2.69 Million CAD | 49.99% |
| 2016 Q3 | 625.48 Thousand CAD | -33.39% |
| 2016 Q2 | 939 Thousand CAD | 52.16% |
| 2015 Q3 | 387.67 Thousand CAD | -14.5% |
| 2015 Q4 | 466.5 Thousand CAD | 20.33% |
| 2015 FY | 1.79 Million CAD | 16.06% |
| 2015 Q2 | 453.4 Thousand CAD | -6.7% |
| 2015 Q1 | 485.95 Thousand CAD | 10.73% |
| 2014 Q1 | 288.5 Thousand CAD | 3.0% |
| 2014 Q2 | 489.13 Thousand CAD | 69.54% |
| 2014 Q3 | 328.79 Thousand CAD | -32.78% |
| 2014 FY | 1.54 Million CAD | -4.05% |
| 2014 Q4 | 438.88 Thousand CAD | 33.48% |
| 2013 Q3 | 331.27 Thousand CAD | 0.52% |
| 2013 Q2 | 329.55 Thousand CAD | -50.79% |
| 2013 FY | 1.61 Million CAD | 10.02% |
| 2013 Q1 | 669.62 Thousand CAD | 62.5% |
| 2013 Q4 | 280.11 Thousand CAD | -15.44% |
| 2012 Q2 | 350.18 Thousand CAD | 13.09% |
| 2012 Q3 | 391.98 Thousand CAD | 11.93% |
| 2012 Q4 | 412.06 Thousand CAD | 5.12% |
| 2012 FY | 1.46 Million CAD | 18.51% |
| 2012 Q1 | 309.66 Thousand CAD | 2.33% |
| 2011 Q4 | 302.6 Thousand CAD | -13.34% |
| 2011 Q3 | 349.19 Thousand CAD | 52.68% |
| 2011 FY | 1.23 Million CAD | 32.91% |
| 2011 Q2 | 228.71 Thousand CAD | -35.53% |
| 2011 Q1 | 354.73 Thousand CAD | 91.34% |
| 2010 Q3 | 264.23 Thousand CAD | 25.04% |
| 2010 Q4 | 185.39 Thousand CAD | -29.84% |
| 2010 FY | 929.4 Thousand CAD | 6.78% |
| 2010 Q1 | 268.44 Thousand CAD | 150.92% |
| 2010 Q2 | 211.32 Thousand CAD | -21.28% |
| 2009 Q4 | 106.98 Thousand CAD | -65.33% |
| 2009 FY | 870.35 Thousand CAD | -17.13% |
| 2009 Q1 | 206.09 Thousand CAD | 116.8% |
| 2009 Q3 | 308.56 Thousand CAD | 24.06% |
| 2009 Q2 | 248.71 Thousand CAD | 20.68% |
| 2008 FY | 1.05 Million CAD | -0.19% |
| 2008 Q4 | 95.06 Thousand CAD | -74.97% |
| 2008 Q2 | 362.88 Thousand CAD | 70.72% |
| 2008 Q1 | 212.55 Thousand CAD | -26.75% |
| 2008 Q3 | 379.77 Thousand CAD | 4.66% |
| 2007 Q2 | 385.82 Thousand CAD | 92.7% |
| 2007 Q4 | 290.19 Thousand CAD | 64.96% |
| 2007 Q3 | 175.91 Thousand CAD | -54.41% |
| 2007 FY | 1.05 Million CAD | 17.89% |
| 2007 Q1 | 200.22 Thousand CAD | -27.17% |
| 2006 Q1 | 159.95 Thousand CAD | -44.05% |
| 2006 FY | 892.58 Thousand CAD | -13.77% |
| 2006 Q3 | 212.43 Thousand CAD | -13.39% |
| 2006 Q2 | 245.26 Thousand CAD | 53.33% |
| 2006 Q4 | 274.93 Thousand CAD | 29.42% |
| 2005 Q2 | 270.93 Thousand CAD | 23.82% |
| 2005 Q4 | 285.87 Thousand CAD | 10.15% |
| 2005 FY | 1.03 Million CAD | 68.05% |
| 2005 Q1 | 218.8 Thousand CAD | 2.3% |
| 2005 Q3 | 259.52 Thousand CAD | -4.21% |
| 2004 Q1 | 115.93 Thousand CAD | 89.29% |
| 2004 FY | 615.97 Thousand CAD | 27.75% |
| 2004 Q3 | 111.35 Thousand CAD | -27.59% |
| 2004 Q2 | 153.77 Thousand CAD | 32.64% |
| 2004 Q4 | 213.89 Thousand CAD | 92.09% |
| 2003 Q4 | 61.24 Thousand CAD | -67.64% |
| 2003 FY | 482.18 Thousand CAD | 0.0% |
| 2003 Q2 | 28.87 Thousand CAD | 0.0% |
| 2003 Q3 | 189.24 Thousand CAD | 555.31% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | 68.097% |
| Skye Bioscience, Inc. | 13.54 Million USD | 74.41% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 90.694% |
| Nascent Biotech, Inc. | 2.22 Million USD | -55.473% |
| Qrons Inc. | 643.67 Thousand USD | -438.602% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 84.91% |
| CSL Limited | 3.44 Billion USD | 99.899% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 88.269% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 31.241% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -275.4% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 93.964% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -734.424% |
| Rebus Holdings, Inc. | 664 Thousand USD | -422.117% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -159.606% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -789.928% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 78.346% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 96.005% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 29.506% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1224.613% |
| SQZ Biotechnologies Company | 85.61 Million USD | 95.951% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -18.881% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -130.832% |
| Mesoblast Limited | 5.9 Million USD | 41.26% |
| Marizyme, Inc. | 19.23 Million USD | 81.981% |
| Genus plc | 147.7 Million USD | 97.653% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 60.511% |
| Pharming Group N.V. | 225.49 Million USD | 98.463% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -69.222% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -158.423% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 58.426% |
| ContraFect Corporation | 56.88 Million USD | 93.906% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 21.363% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -134.445% |
| IMV Inc. | 37.7 Million USD | 90.806% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -24.244% |
| MultiCell Technologies, Inc. | 567.42 USD | -610885.866% |
| ONE Bio Corp. | 6.44 Million USD | 46.199% |
| Accustem Sciences Inc. | 3.74 Million USD | 7.462% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 95.966% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -551.711% |
| Q BioMed Inc. | 3.43 Million USD | -0.88% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 85.973% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -31.944% |
| Biomind Labs Inc. | 994.18 Thousand USD | -248.714% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 96.51% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -97.016% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 48.395% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -85.953% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 13967.424% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -88.92% |
| GB Sciences, Inc. | 1.42 Million USD | -144.057% |
| Alpha Cognition Inc. | 9.7 Million USD | 64.28% |
| HST Global, Inc. | 140.9 Thousand USD | -2360.386% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -208.19% |
| Halberd Corporation | 74.84 Thousand USD | -4532.233% |
| Enzolytics Inc. | 2.17 Million USD | -59.066% |
| Agentix Corp. | 1.37 Million USD | -152.731% |
| Resverlogix Corp. | 12.71 Million USD | 72.728% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 5.036% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.774% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -232.074% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -44.156% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -119.511% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -1.817% |
| AVAX Technologies, Inc. | 7.31 Million USD | 52.576% |
| Zenith Capital Corp. | 8.94 Million USD | 61.234% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.58% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -19800.442% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -41.198% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1921.384% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -80.48% |
| Kadimastem Ltd | 2.41 Million USD | -43.846% |
| Helix BioMedix, Inc. | 1.97 Million USD | -75.801% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1810.271% |
| LadRx Corporation | 3.81 Million USD | 9.049% |
| Cell Source, Inc. | 4.32 Million USD | 19.848% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -275.4% |
| NovAccess Global Inc. | 2.46 Million USD | -40.543% |
| Affymax, Inc. | 39.38 Million USD | 91.198% |
| Itoco Inc. | 919.14 Thousand USD | -277.184% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 18.204% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -209.817% |
| Mobile Lads Corp. | 554.54 Thousand USD | -525.17% |
| CytoDyn Inc. | 18.05 Million USD | 80.802% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -13674.31% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1475.285% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -144.181% |
| SYBLEU INC | 160.87 Thousand USD | -2054.986% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -90.873% |
| International Stem Cell Corporation | 5.27 Million USD | 34.228% |
| Bioxytran, Inc. | 3.82 Million USD | 9.248% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -6485.722% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -16942.01% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 90.44% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -114.268% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -371.146% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -11.439% |
| Neutra Corp. | 243.82 Thousand USD | -1321.886% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 80.141% |
| PureTech Health plc | 144.59 Million USD | 97.602% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 83.08% |
| IXICO plc | 4.7 Million USD | 26.347% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 60.59% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.056% |
| CSL Limited | 3.89 Billion USD | 99.911% |
| Cellectis S.A. | 97.32 Million USD | 96.438% |